Polymer-free Amphilimus™ eluting stent for below the knee arteries. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption. This may contribute to maximize results in diabetic patients.
Controlled and directed drug elution by the Abluminal Reservoir Technology, without the use of any polymer.
Maximized efficacy, especially in Diabetic Patients, due to the proprietary Amphilimus™ formulation, a combination of Sirolimus and Fatty Acid.
Proven haemo/biocompatibility enabled by the Bio Inducer Surface, which accelerates the rate of endothelialization and reduces thrombogenicity.
The images shown within this pages are of a purely illustrative nature and not intended to depict reality.
Manufactured by CID S.p.A member of Alvimedica Group.